文献速递消化系统肿瘤

NAPOLI-1 脂质体伊立替康治疗转移性胰腺癌的3期研究:最终总生存分析和长期生存者特征

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
PubMed 文献 · Eur J Cancer · 2019-01-14

NAPOLI-1 3期试验最终生存分析显示,脂质体伊立替康(nal-IRI)联合5-氟尿嘧啶/亚叶酸钙(5-FU/LV)对比5-FU/LV单药在转移性胰腺导管腺癌患者中维持总生存获益(6.2 vs 4.2个月;HR 0.75;95%CI 0.57-0.99)。nal-IRI+5-FU/LV组1年总生存率为26%,5-FU/LV组为16%。nal-IRI+5-FU/LV组中长期生存(≥1年)相关基线特征包括Karnofsky体能状态评分≥90、年龄≤65岁、较低CA19-9水平、中性粒细胞与淋巴细胞比值≤5和无肝转移。

要点

  • nal-IRI+5-FU/LV对比5-FU/LV维持总生存获益:6.2 vs 4.2个月,HR 0.75(95%CI 0.57-0.99)。
  • 1年总生存率:nal-IRI+5-FU/LV组26% vs 5-FU/LV组16%。
  • 长期生存相关基线特征:KPS≥90、年龄≤65岁、较低CA19-9、NLR≤5、无肝转移。

核心结论

  • 在延长随访中,nal-IRI+5-FU/LV对比5-FU/LV的生存获益得以维持,并识别出生存≥1年的预后标志物。

研究设计与样本

  • 全球3期NAPOLI-1试验,将转移性胰腺导管腺癌患者随机分配至nal-IRI+5-FU/LV组(n=117)、nal-IRI组(n=151)或5-FU/LV组(n=149),每6周周期的前4周给药。
  • 截至2015年11月16日,共发生382例总生存事件。
  • 比较总体人群与生存≥1年患者的基线特征和疗效。

主要发现

  • nal-IRI+5-FU/LV组 vs 5-FU/LV组的中位总生存期分别为6.2个月 vs 4.2个月(HR 0.75;95%CI 0.57-0.99)。
  • nal-IRI+5-FU/LV组 vs 5-FU/LV组的1年总生存率估计分别为26% vs 16%。
  • 中位无进展生存期、客观缓解率和疾病控制率也倾向于nal-IRI+5-FU/LV治疗。
  • 未检测到新的安全性问题。

关键数值与推荐

  • nal-IRI+5-FU/LV组中与长期生存相关的基线特征:Karnofsky体能状态评分≥90、年龄≤65岁、较低CA19-9水平、中性粒细胞与淋巴细胞比值≤5和无肝转移。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is approved for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. This approval was based on significantly improved median overall survival compared with 5-FU/LV alone (6.1 vs 4.2 months; hazard ratio [HR], 0.67) in the global phase 3 NAPOLI-1 trial. Here, we report the final survival analysis and baseline characteristics associated with long-term survivors (survival of ≥1 year) in the NAPOLI-1 trial. PATIENTS AND METHODS: Patients with mPDAC were randomised to receive nal-IRI + 5-FU/LV (n = 117), nal-IRI (n = 151), or 5-FU/LV (n = 149) for the first 4 weeks of 6-week cycles. Baseline characteristics and efficacy in the overall population were compared with those in patients who survived ≥1 year. Through 16th November 2015, 382 overall survival events had occurred. RESULTS: The overall survival advantage for nal-IRI+5-FU/LV vs 5-FU/LV was maintained from the original nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1) analysis (6.2 vs 4.2 months, respectively; HR, 0.75; 95% confidence interval: 0.57-0.99). Median progression-free survival, objective response rate and disease control rate also favoured nal-IRI+5-FU/LV therapy. Estimated one-year overall survival rates were 26% with nal-IRI+5-FU/LV and 16% with 5-FU/LV. Baseline characteristics associated with long-term survival in the nal-IRI+5-FU/LV arm were Karnofsky performance status ≥90, age ≤65 years, lower CA19-9 levels, neutrophil-to-lymphocyte ratio ≤5 and no liver metastases. No new safety concerns were detected. CONCLUSIONS: The survival benefits of nal-IRI+5-FU/LV versus 5-FU/LV were maintained over an extended follow-up, and prognostic markers of survival ≥1 year were identified. CLINICAL TRIAL REGISTRATION NUMBER: NCT01494506.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019. PMID: 30654298. doi:10.1016/j.ejca.2018.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。